scholarly journals CpG oligodeoxynucleotide as immune adjuvant enhances photodynamic therapy response in murine metastatic breast cancer

2013 ◽  
Vol 7 (11-12) ◽  
pp. 897-905 ◽  
Author(s):  
Yumin Xia ◽  
Gaurav K. Gupta ◽  
Ana P. Castano ◽  
Pawel Mroz ◽  
Pinar Avci ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Photodynamic Therapy ◽  
Metastatic Breast Cancer ◽  
Metastatic Breast ◽  
Therapy Response ◽  
Cpg Oligodeoxynucleotide ◽  
Immune Adjuvant

scholarly journals Molecular Biomarkers for Prediction of Targeted Therapy Response in Metastatic Breast Cancer: Trick or Treat?

2017 ◽  
Vol 18 (1) ◽  
pp. 85 ◽  
Author(s):  
Angela Toss ◽  
Marta Venturelli ◽  
Chiara Peterle ◽  
Federico Piacentini ◽  
Stefano Cascinu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Targeted Therapy ◽  
Metastatic Breast ◽  
Therapy Response ◽  
Molecular Biomarkers

scholarly journals Dysmetabolic Circulating Tumor Cells Are Prognostic in Metastatic Breast Cancer

Cancers ◽  
2020 ◽  
Vol 12 (4) ◽  
pp. 1005 ◽  
Author(s):  
Giulia Brisotto ◽  
Eva Biscontin ◽  
Elisabetta Rossi ◽  
Michela Bulfoni ◽  
Aigars Piruska ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Metastatic Breast ◽  
Therapy Response ◽  
Label Free ◽  
Breast Cancer Patients ◽  
Combining Data ◽  
Definition Of

Circulating tumor cells (CTCs) belong to a heterogeneous pool of rare cells, and a unequivocal phenotypic definition of CTC is lacking. Here, we present a definition of metabolically-altered CTC (MBA-CTCs) as CD45-negative cells with an increased extracellular acidification rate, detected with a single-cell droplet microfluidic technique. We tested the prognostic value of MBA-CTCs in 31 metastatic breast cancer patients before starting a new systemic therapy (T0) and 3–4 weeks after (T1), comparing results with a parallel FDA-approved CellSearch (CS) approach. An increased level of MBA-CTCs was associated with: i) a shorter median PFS pre-therapy (123 days vs. 306; p < 0.0001) and during therapy (139 vs. 266 days; p = 0.0009); ii) a worse OS pre-therapy (p = 0.0003, 82% survival vs. 20%) and during therapy (p = 0.0301, 67% survival vs. 38%); iii) good agreement with therapy response (kappa = 0.685). The trend of MBA-CTCs over time (combining data at T0 and T1) added information with respect to separate evaluation of T0 and T1. The combined results of the two assays (MBA and CS) increased stratification accuracy, while correlation between MBA and CS was not significant, suggesting that the two assays are detecting different CTC subsets. In conclusion, this study suggests that MBA allows detection of both EpCAM-negative and EpCAM-positive, viable and label-free CTCs, which provide clinical information apparently equivalent and complementary to CS. A further validation of proposed method and cut-offs is needed in a larger, separate study.

scholarly journals Dysmetabolic circulating tumor cells are prognostic in metastatic breast cancer

2019 ◽  
Author(s):  
Giulia Brisotto ◽  
Eva Biscontin ◽  
Elisabetta Rossi ◽  
Michela Bulfoni ◽  
Aigars Piruska ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Prognostic Value ◽  
Metastatic Breast ◽  
Therapy Response ◽  
Prognostic Information ◽  
Definition Of ◽  
Over Time

ABSTRACTThe prognostic value of the circulating tumor cells (CTCs), defined as EpCAM+, Cytokeratin (8, 18, 19)+ and CD45-nucleated cells, has been provided in metastatic breast cancer (mBC), with Level I of evidence. However, CTCs belong to a heterogeneous pool of rare cells, and there isn’t consensus on an univocal definition of CTCs. Here, we present a definition of metabolically altered CTCs (MBA-CTC) as CD45-negative cells with an increased extracellular acidification rate (iECAR), supported by the presence of iECAR among the hallmarks of cancer. We tested the prognostic value of MBA-CTC present in mBC patients before starting a new systemic therapy (T0) and 3-4 weeks after (T1). Samples were analyzed in parallel with CellSearch platform (CS). Standard RECIST criteria were used to determine patients’ responses to treatment.In our cohort of n=31 mBC patients, a level of MBA-CTCs above the cut-off was associated with: i) a shorter median PFS both pre-therapy (123 days vs 306; p<0.0001) and during therapy (139 vs 266 days; p= 0.0009); ii) a worse OS both pre-therapy (p=0.0003, 82% survival vs 20%) and during therapy (p=0.0301, 67% survival vs 38%); iii) good agreement with therapy response (kappa=0.685). Both the trend of MBA-CTCs over time and the combined results of the two assays (MBA and CS) enabled more accurate stratification. MBA and CS results showed fair (K=0.33) and poor (K=0.077) agreement at T0 and T1, respectively. This fact and the increased accuracy in combining results suggest that the assays detect different CTC subsets. In conclusion, MBA-CTCs does provide prognostic information at least equivalent to CS, and are even more informative when analyzed over time or combined with CS-CTCs.

scholarly journals Photodynamic Therapy with Verteporfin for Choroidal Metastasis Refractory to Radiotherapy

2019 ◽  
Vol 12 (3) ◽  
pp. 861-865
Author(s):  
Raymond Zhou ◽  
David Reichstein
Keyword(s):  
Breast Cancer ◽  
Photodynamic Therapy ◽  
Metastatic Breast Cancer ◽  
Primary Breast Cancer ◽  
External Beam Radiotherapy ◽  
Metastatic Breast ◽  
Eye Disease ◽  
External Beam ◽  
Choroidal Metastasis

A 54-year old female with longstanding metastatic breast cancer was referred for management of choroidal metastases. She was first treated with external beam radiotherapy and experienced some response before later suffering progression of her eye disease. We then treated her using full fluence Photodynamic therapy (PDT) with Verteporfin, which resulted in regression of her lesions until she passed away due to other illnesses. This is the first documented successful application of PDT for choroidal metastasis from a primary breast cancer refractory to external beam radiotherapy.

In vitro and in vivo effects of photodynamic therapy on metastatic breast cancer cells pre-treated with zoledronic acid

2014 ◽  
Vol 11 (3) ◽  
pp. 426-433
Author(s):  
Margarete K. Akens ◽  
Lisa Wise-Milestone ◽  
Emily Won ◽  
Joerg Schwock ◽  
Albert J.M. Yee ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Photodynamic Therapy ◽  
Metastatic Breast Cancer ◽  
Zoledronic Acid ◽  
Cancer Cells ◽  
Breast Cancer Cells ◽  
Metastatic Breast ◽  
In Vivo Effects

scholarly journals Photodynamic therapy of intradermal metastatic breast cancer (literature review)

2019 ◽  
Vol 8 (3) ◽  
pp. 36-42
Author(s):  
R. I. Rakhimzhanova ◽  
N. A. Shanazarov ◽  
D. E. Turzhanova
Keyword(s):  
Breast Cancer ◽  
Photodynamic Therapy ◽  
Metastatic Breast Cancer ◽  
Therapeutic Effect ◽  
High Efficiency ◽  
Radiation Treatment ◽  
Metastatic Breast ◽  
Breast Metastases ◽  
The World ◽  
Promising Treatment

In recent years, an increase in the incidence of breast cancer has been observed throughout the world, and in 20% of cases, with the development of intradermal metastases. The possibilities of surgical and radiation treatment of intradermal breast metastases are quite limited, and the effectiveness of polychemotherapy using standard regimens does not exceed 22–27%, while the period of remission, in general, is only 2–3 months. Photodynamic therapy (PDT) is a promising treatment for intradermal metastases of breast cancer. The experience of using PDT in this nosology is quite limited, but the results show its high efficiency and safety. Thus, several Russian studies are devoted to assessing the effectiveness of PDT of intradermal breast metastases with Photolon, a chlorin series photosensitizer. According to the authors, the therapeutic effect was achieved in 85–97% of patients (the percentage of patients with full and partial effect was 73–85%). Studies on the effectiveness of PDT in patients with the same nosology using the Photosens photosensitizer show a slightly lower effectiveness – the therapeutic effect was achieved in 81.8% of cases, while the proportion of patients with full and partial effect was only about 50%. Several studies have been carried out abroad on models of metastatic breast cancer using new photosensitizers (e.g. sodium sinoporphyrin) and new combined PDT regimens (e.g. adjuvant PDT with fluorouracil or Capecitabine). The obtained results demonstrate the promise of new approaches: PDT with sodium sinoporphyrin inhibited the growth of both the tumor itself and its metastases; the use of adjuvant regimens led to an increase in the tumor cells differentiation in the animal model, the cessation of tumor and metastatic foci growth.

Sign in / Sign up

Export Citation Format

Share Document